Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

Beyond PPIs: Evan S. Dellon, MD, on Approaches Treating to EoE

When discussing treatment for eosinophilic esophagitis (EoE), often the first-line treatment is a choice between diet and medication, Evan S. Dellon, MD, said during his presentation at the 2023 ACG Postgraduate Course on October 22, in Vancouver, British Columbia, Canada.

“And it doesn’t always have to be either/ or,” Dr Dellon said. “Ultimately, it all comes down to shared decision making and patient and provider preference.”

Dr Dellon is a professor of medicine and director of the Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Current EoE treatments include nonpharmacologic treatments such as dietary interventions and esophageal dilation, while and pharmacologic treatments comprise proton pump inhibitors (PPIs), topical corticosteroids, mast cell stabilizers, immunomodulators, biologics, and small molecules.

Dietary interventions have become the first-line treatment of EoE and are as effective as medication therapies, according to international guidelines.

According to research by Angel Arias and colleagues published in Gastroenterology, elemental diets were found to be effective for 90.8% of the cases; 6-food elimination diets (SFEDs) were found to be effective for 72.1% of the cases; and allergy test result-directed food elimination for 45.5% of cases. Elemental diets and SFEDs were the most effective, “achieving <15 eosinophils/high-power field in 90.8% and 72.1% of patients, respectively,” Dr Dellon said.

Among topical corticosteroids, both fluticasone and budesonide have shown statistically significant decreases in eosinophil count. However, “fluticasone showed faster inset of action and greater immunologic improvement compared to budesonide,” Dr Dellon explained.

Dupilumab—a biologic approved for the treatment of multiple type 2 inflammatory diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps—is indicated for EoE among patients 12 years and older, 40 kg and above, with a dosing of 300 mg weekly.

“While both medication and diet therapies are effective,” Dr Dellon concluded, they each have limitations and can be used together in a treatment program for EoE.

 

Reference:

Dellon E. Eosinophilic esophagitis: Beyond PPI therapy. Session 2B: The esophagus and more: Elucidating the esophageal enigmas. Presented at: 2023 ACG Postgraduate Course. Vancouver, Canada. October 22, 2023.

© 2023 HMP Global. All Rights Reserved.

Advertisement

Advertisement

Advertisement